Citra-Lock™ 30%

Using Citra-Lock 30%

• improves overall patency rates
• reduces catheter-related infections
• reduces major bleeding for both tunneled an untunneld Central Venous
• Catheters (CVC)

Anti Microbial
Since the introduction of Citra-Lock (46,7%) to the renal departmant of
St.Bard’s renal unit (Royal London Hospital) has proven record in
managing MRSA.
The number of MRSA infections has fallen from 2,27/1000 patiens catheter
days to 1,36/1000 patiens catheter days.
Citra-Lock intervention provides significant benefit to patiens, provides an
extra 2-3 bed days to the hospital an provides savings of € 145.000,- .

Anti Coagulant
Citra-Lock is based on higly concentrated trisodium citrate that prevents
clotting and therefore helps maintaining high flow rates whilst greatly
reducing the need for Urokinase/tPA and otheter replacements.

Reducing Biofilm
Trisodium citrate (TSC) lowers infection rates by reducing biofilm
formation in hemodialysis catheters. The study of Bosma (2009)
demonstrates an in vivo reduction of intraluminal catheter biofilm
formation and bacterial colonizasion with the use of TSC 30% for HD

catheter locking. By this mechanism, prevention of catheter-related
infections by TSC can be largely explained.

Increase Safety & Simplified handling
The Citra-Lock vial features a drip free Luer-Slip/Luer-Lock connector:

•  preventing microbial contaminationluer slip lock
•  protecting against needle stick injuries
•  reducing handling steps
•  promoting intuitive handing

Citra-Lock™ 30% 5ml vial
Boxes contain 20 x 5ml vial
Art.nr. 24060203